Revascularization Strategy in Myocardial Infarction with Multivessel Disease

The proportion of patients with multivessel coronary artery disease in individuals experiencing acute coronary syndrome (ACS) varies based on age and ACS subtype. In patients with ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock, the prognostic benefit of complete revascu...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical medicine 2024-04, Vol.13 (7), p.1918
Main Authors:	Jobs, Alexander, Desch, Steffen, Freund, Anne, Feistritzer, Hans-Josef, Thiele, Holger
Format:	Article
Language:	eng
Subjects:	acute coronary syndrome Acute coronary syndromes Angina pectoris Cardiovascular disease Care and treatment Coronary vessels Development and progression Diagnosis Evaluation Heart attack Heart attacks Hemodynamics Ischemia Kidneys Medical imaging Morphology Mortality multivessel disease Myocardial revascularization NSTEMI Patient outcomes Patients revascularization STEMI
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The proportion of patients with multivessel coronary artery disease in individuals experiencing acute coronary syndrome (ACS) varies based on age and ACS subtype. In patients with ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock, the prognostic benefit of complete revascularization has been demonstrated by several randomized trials and meta-analyses, leading to a strong guideline recommendation. However, similar data are lacking for ACS without ST-segment elevation (NSTE-ACS). Non-randomized data suggesting a benefit from complete revascularization in non-ST-segment elevation myocardial infarction (NSTEMI) are prone to selection bias and should be interpreted with caution. A series of large randomized controlled trials have been initiated recently to address these open questions.
ISSN:	2077-0383 2077-0383